SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the business's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $4.82, for a total value of $24,100.00. Following the transaction, the insider owned 261,388 shares of the company's stock, valued at $1,259,890.16. This represents a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Trading Up 3.6%

---

---

NASDAQ:SOPH opened at $5.04 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 12-month low of $2.59 and a 12-month high of $5.70. The business has a 50 day simple moving average of $4.79 and a 200 day simple moving average of $4.76. The firm has a market capitalization of $344.85 million, a P/E ratio of -9.87 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Guggenheim boosted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Finally, BTIG Research boosted their price objective on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus price target of $7.50.

View Our Latest Report on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the stock. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth $48,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $50,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the third quarter valued at $49,000. Perkins Capital Management Inc. acquired a new position in SOPHiA GENETICS during the fourth quarter valued at $49,000. Finally, Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter valued at $54,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Featured Articles

• Five stocks we like better than SOPHiA GENETICS

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].